Clinical trials: Constipation Predominant Irritable Bowel Syndrome
Irritable Bowel Syndrome
Phase 2 Study of MD-1100 Acetate on Gastrointestinal Transit in Patients With C-IBS
The primary objective of this trial is to compare the dose-ranging pharmacodynamic effects of orally administered placebo, and 100 and 1000 ug qd of MD-1100 Acetate on gastrointestinal transit in patients with C-IBS.
- Trial name
- NCT00258193
- Testing
- MD-1100 Acetate
- Where
- United States
- Volunteers
- 36 people
- Sponsor
- Ironwood Pharmaceuticals, Inc.
Irritable Bowel Syndrome With Constipation
A Multistrain Probiotic in Patients With Irritable Bowel Syndrome With Predominant Constipation
Probiotics efficacy is mainly assessed by subjective endpoints such as the FDA responder rate or global relief, which partly explain contradictory results obtained in clinical trials with probiotic bacteria.
- Trial name
- EPORE (NCT04997057)
- Testing
- Probiotics mixture
- Where
- France
- Volunteers
- 80 people
- Sponsor
- CEN Biotech
Irritable Bowel Syndrome
Investigation of the Safety and Efficacy of Renzapride in Constipation Predominant Irritable Bowel Syndrome (IBS)
The purpose of the study is to investigate whether renzapride will help alleviate the symptoms associated with constipation predominant irritable bowel syndrome in female patients.
- Trial name
- NCT00268879
- Testing
- Renzapride
- Where
- United Kingdom
- Volunteers
- 1,821 people
- Sponsor
- Alizyme
Irritable Bowel Syndrome-IBS
Effect of Different Dietary Therapies on Intestinal Barrier Integrity in Patients With Irritable Bowel Syndrome
This study aims to evaluate the effects of different dietary treatments on intestinal integrity in female subjects aged 19-50 years previously diagnosed with constipation-predominant irritable bowel syndrome (IBS).
- Trial name
- NCT06421922
- Testing
- Group 1 received a regular constipation diet, Group 2 received a constipation diet rich in soluble fiber, Group 3 received a constipation diet supplemented with probiotic yogurt.
- Where
- Turkey (Türkiye)
- Volunteers
- 60 people
- Sponsor
- Gulhane Training and Research Hospital
Constipation-predominant Irritable Bowel Syndrome
Effect of Lubiprostone on Small Bowel Contractions in Female Patients With Constipation Irritable Bowel Syndrome (C-IBS)
Irritable Bowel Syndrome (IBS) is a common disorder, defined by symptom-based diagnostic criteria. The pathogenesis is multifactorial and gut motor dysfunction is considered to be a contributing factor.
- Trial name
- NCT01085643
- Testing
- Lubiprostone
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- Cedars-Sinai Medical Center
Constipation-predominant Irritable Bowel Syndrome
Neomycin and Rifaximin Plus Neomycin in Treating Methane Positive Constipation Predominant Irritable Bowel Syndrome
In this study the investigators aim to compare the efficacy of neomycin to a combination of rifaximin and neomycin in the treatment of C-IBS subjects with methane on their breath test.
- Trial name
- C-IBS (NCT00945334)
- Testing
- Neomycin, Rifaximin
- Where
- 2 sites in United States
- Volunteers
- 37 people
- Sponsor
- Mark Pimentel, MD
Constipation Predominant Irritable Bowel Syndrome
A 12-Week Study With a 4-Week Randomized Withdrawal Period to Evaluate the Efficacy and Safety of Tenapanor for the Treatment of IBS-C
This phase 3, 12-week, randomized, double-blind, placebo-controlled, multi-center study will evaluate the safety and efficacy of tenapanor in subjects with constipation-predominant irritable bowel syndrome (IBS-C) as defined by…
- Trial name
- T3MPO-1 (NCT02621892)
- Testing
- Tenapanor
- Where
- 111 sites in United States
- Volunteers
- 606 people
- Sponsor
- Ardelyx
Irritable Bowel Syndrome Constipation Predominant
Effects of ROSE-010 on GI Transit in Constipation Predominant Irritable Bowel Syndrome (C-IBS) Patients
This trial will study the effects of an investigational (not FDA approved) medication, ROSE-010, on the movement of food through the stomach, small intestine and colon in females with constipation predominant irritable bowel…
- Trial name
- NCT01056107
- Testing
- ROSE-010
- Where
- United States
- Volunteers
- 52 people
- Sponsor
- Mayo Clinic
Irritable Bowel Syndrome
Olorinab in Irritable Bowel Syndrome With Predominant Constipation (IBS-C) and Irritable Bowel Syndrome With Predominant Diarrhea (IBS-D)
The purpose of this study is to determine whether olorinab is a safe and effective treatment for abdominal pain in participants with irritable bowel syndrome (IBS).
- Trial name
- CAPTIVATE (NCT04043455)
- Testing
- Olorinab
- Where
- 69 sites in United States
- Volunteers
- 273 people
- Sponsor
- Arena Pharmaceuticals
Constipation-predominant Irritable Bowel Syndrome
Assessment of Responsiveness to Treatment by Experience Sampling Method
Reliable evaluation of symptoms and their improvement during treatment is crucial in both diagnosing and evaluating response to treatment in IBS.
- Trial name
- NCT03336034
- Where
- Netherlands
- Volunteers
- 16 people
- Sponsor
- Maastricht University Medical Center
Constipation-predominant Irritable Bowel Syndrome
A Chinese Herbal Medicine for IBS-C
This double-blind, placebo-controlled randomized pilot clinical trial will test the hypothesis that granules of CDD-2105, a Chinese herbal medicine formula, will have efficacy in alleviating constipation and abdominal pain in…
- Trial name
- CDD2105RCT1 (NCT06319729)
- Testing
- CDD-2105
- Volunteers
- 78 people
- Sponsor
- Hong Kong Baptist University
Irritable Bowel Syndrome
Effect of Olorinab on Gastrointestinal Transit in Patients With Irritable Bowel Syndrome
A Phase 1b study to determine the effect of oral olorinab on gastrointestinal transit in adult participants with irritable bowel syndrome (IBS).
- Trial name
- NCT04655599
- Testing
- Olorinab
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Arena Pharmaceuticals
Irritable Bowel Syndrome With Constipation (IBS-C)
Phase III Study to Evaluate the Efficacy and Safety of ASP0456 in Patients With Constipation Predominant Irritable Bowel Syndrome
The objective of this study is to evaluate the efficacy and safety of ASP0456 in patients with constipation predominant irritable bowel syndrome (IBS-C).
- Trial name
- NCT02316899
- Testing
- linaclotide
- Where
- 61 sites in Japan
- Volunteers
- 500 people
- Sponsor
- Astellas Pharma Inc
Constipation-predominant Irritable Bowel Syndrome
Laser Acupuncture on Irritable Bowel Syndrome in Females
The aim of the study to investigate effect of laser acupuncture on constipation predominant irritable bowel syndrome in female patients
- Trial name
- NCT05757037
- Testing
- laser acupuncture
- Where
- Egypt
- Volunteers
- 50 people
- Sponsor
- Cairo University
Irritable Bowel Syndrome Characterized by Constipation
Botanical Tincture for Symptoms of Irritable Bowel Syndrome
The main purpose of this study is to investigate the feasibility of a follow-up larger RCT on the efficacy of Botanical Tincture to relieve abdominal pain in people with Irritable Bowel Syndrome Constipation Predominant (IBS-C).
- Trial name
- NCT03923322
- Testing
- Botanical Tincture
- Where
- United States
- Sponsor
- Stamford Hospital
Bloating, Rifaximin
Rifaximin Treatment in Bloating Predominant Functional Bowel Disorders
This randomized, double-blind, placebo-controlled trial will evaluate the effects of a 14-day course of rifaximin on bloating symptoms, gut microbiota, microbial metabolites, and intestinal gases in adults with Rome V irritable…
- Conditions
- Bloating, Rifaximin, Functional Bowel Disorder, Irritable Bowel Syndrome
- Trial name
- NCT07522255
- Testing
- Rifaximin (drug)
- Where
- Thailand
- Volunteers
- 78 people
- Sponsor
- Mahidol University
Constipation Predominant Irritable Bowel Syndrome
The Efficacy of AZD1722 in Constipation Predominant Irritable Bowel Syndrome (IBS-C)
This phase 2, randomized, double blind, placebo-controlled, multi-center study will evaluate the safety and efficacy of three dose levels of AZD1722 in subjects with constipation predominant IBS (IBS-C) as defined by the ROME III…
- Trial name
- NCT01923428
- Testing
- AZD1722
- Where
- 4 sites in United States
- Volunteers
- 356 people
- Sponsor
- Ardelyx
Irritable Bowel Syndrome, Diarrhea- Irritable Bowel Syndrome
To Study the Effect of Short-chain Fructooligosaccharides in Women With Irritable Bowel Syndrome
To evaluate whether there is clinical improvement through the scales (Bristol, IBS severity score, and IBS quality of life) in women with irritable bowel syndrome after administration of SC-FOS (short-chain…
- Conditions
- Irritable Bowel Syndrome, Diarrhea- Irritable Bowel Syndrome, Constipation-predominant Irritable Bowel Syndrome
- Trial name
- NCT05941650
- Testing
- Short Chain Fructooligosaccharides, Corn Starch
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Universidad Autonoma de Chihuahua
Patient Satisfaction
Study of Comparative Effectiveness of Prucalopride and Lubiprostone in Constipation Predominant Irritable Bowel Syndrome
This will be a semi-experimental study on constipation predominant IBS patient. One group of patient will receive prucalopride 2mg daily and another group of patient will receive lubiprostone 8 microgram twice daily.
- Trial name
- NCT04985669
- Testing
- Prucalopride 2mg
- Where
- Bangladesh
- Volunteers
- 140 people
- Sponsor
- Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh
Irritable Bowel Syndrome
Study to Evaluate the Role of Itopride HCI in Patients With Irritable Bowel Syndrome With Predominant Constipation
Patients suffering from Irritable Bowel Syndrome with predominant constipation will be provided with the study medication. The study medication will be evaluated for its efficacy in relieving the symptoms
- Trial name
- NCT01027260
- Testing
- Itopride HCI 50 mg, Itopride HCI 100 mg
- Where
- 4 sites in Pakistan
- Volunteers
- 268 people
- Sponsor
- Abbott